No benefit from daratumumab, bortezomib and dexamethasone (D‐Vd) in real‐world patients with functional high‐risk multiple myeloma: A report from the Myeloma and Related Diseases Registry
The data from the Myeloma and Related Diseases Registry that support the findings of this study are available on request and following approval from the corresponding author and the registry. The data are not publicly available due to privacy and ethical restrictions. The data access policy is available at www.mrdr.net.au.
Authors
- Andrew Spencer (ORCID: https://orcid.org/0000-0002-0531-7424)
- P. Joy Ho (ORCID: https://orcid.org/0000-0002-2811-8671)
- Amit Khot (ORCID: https://orcid.org/0000-0002-9210-5373)
- Elizabeth S. Moore (ORCID: https://orcid.org/0000-0003-2502-6429)
- Sueh‐li Lim (ORCID: https://orcid.org/0000-0001-6990-8832)
- Erica M. Wood (ORCID: https://orcid.org/0000-0001-7527-2340)
- Cameron Wellard (ORCID: https://orcid.org/0000-0002-6115-5394)
- Hang Quach (ORCID: https://orcid.org/0000-0002-4796-3352)
- Simon James Harrison (ORCID: https://orcid.org/0000-0003-4555-6582)
- Rajeev Rajagopal (ORCID: https://orcid.org/0009-0006-7414-3575)
Institutions
- The University of Sydney (AU)
- The Royal Melbourne Hospital (AU)
- The University of Melbourne (AU)
- Royal Prince Alfred Hospital (AU)
- Middlemore Hospital (NZ)
- Peter MacCallum Cancer Centre (AU)
- Monash Medical Centre (AU)
- St Vincent's Hospital Melbourne (AU)
- Monash Health (AU)
- Alfred Health (AU)
- Monash University (AU)
Publication Details
- Journal
- British Journal of Haematology
- Published
- 2025-11-08
- DOI
- https://doi.org/10.1111/bjh.70238
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00